Biotechnology News & Press Release Distribution

Biotechnology

APAC
Global

Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022

* Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated * Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development * Additional data presented by Brii's licensing part...

2022-10-19 20:00 1781

EDAN Forays into Molecular Point-of-Care Market with Its First-Ever Molecular Diagnostics Solution Released at Medlab Asia 2022

Developed based on Loop-Mediated Isothermal Amplification (LAMP), the new molecular diagnostics analysis system, ClariLight CL30, gives on-the-spot results and empowers physicians for early infectious disease diagnostics because of its agility, fast and flexibility. BANGKOK, Thailand, Oct. 19, 2...

2022-10-19 19:59 1693

EDAN Forays into Molecular Point-of-Care Market with Its First-Ever Molecular Diagnostics Solution Released at Medlab Asia 2022

Sirnaomics to Present Latest Developments on GalAhead™ Therapeutic Platform at Upcoming Industry Conferences

Sirnaomics Chief Technology Officer Dmitry Samarsky is a featured speaker at the RNA LeadersUSA Congress and 18th Drug Discovery Innovation Programme Gaithersburg, Md. and Suzhou, China, Oct. 19, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK) a leading ...

2022-10-19 14:55 1736

MedAlliance to be Acquired by Cordis

GENEVA, Oct. 19, 2022 /PRNewswire/ -- Swiss-based medical technology company MedAlliance has announced it has entered into an agreement with Cordis for an acquisition which includes an initial investment of$35M and upfront closing payment of$200M, regulatory achievement milestones of up to $125M ...

2022-10-19 08:00 1700

STANDIGM TO ATTEND BIO-EUROPE® 2022

Standigm will present AI-driven drug discovery technology at the conference CAMBRIDGE, England, Oct. 18, 2022 /PRNewswire/ -- Standigm , the workflow AI-driven drug discovery company, today announced that it will be represented at the 28th annual BIO-Europe

2022-10-19 01:50 1465

CARsgen Announces NDA Acceptance of BCMA CAR T Zevor-cel (CT053) by China NMPA

SHANGHAI, Oct. 18, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces thatthe National Medical Products Administration (NMPA) ofChina has a...

2022-10-18 20:50 2050

Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea

GUANGZHOU, China, Oct. 18, 2022 /PRNewswire/ -- Zhiyi Biotech announced that FDA has approved the Company's Investigational New Drug (IND) application to develop SK10 (InactivatedBacteroides fragilis) for the treatment of Chemotherapy-induced Diarrhea (CID) . The approval of this IND authorizes Z...

2022-10-18 20:35 876

Zhiyi Biotech Received Clinical Approval from U.S. FDA for SK10 in Chemotherapy-induced Diarrhea

Alphyn Biologics Announces Enrollment Passes Halfway Point in Phase2a Clinical Trial of Mild-to-Moderate Atopic Dermatitis Treatment

Study evaluates AB-101a for patients with and without concurrent bacterial infection ANNAPOLIS, Md., Oct. 18, 2022 /PRNewswire/ -- Alphyn Biologics, a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that enrollment in its Phase2a clinical t...

2022-10-18 19:30 1181

WeTrade Group Announces the Launch of Global Payment System WTPay and Development Plan of Health Business

BEIJING, Oct. 18, 2022 /PRNewswire/ -- WeTrade Group Inc. ("WeTrade" or the "Company") (NASDAQ: WETG), a global diversified "software as a service" ("SaaS") technology service provider which is committed to providing technical support and digital transformation tools for enterprises across differ...

2022-10-18 17:02 2751

WeTrade Group Announces the Launch of Global Payment System WTPay and Development Plan of Health Business

NEC Selected as Technology Partner in the Implementation of Biometric Solutions for NIISe

KUALA LUMPUR, Malaysia, Oct. 18, 2022 /PRNewswire/ -- Leading IT and Network Technologies company, NEC Corporation of Malaysia Sdn Bhd (NEC Malaysia) has been awarded the sub-contract for the implementation of its class leading Automated Biometric Identification System (NEC ABIS) and Border Contr...

2022-10-18 17:01 1647

NEC Selected as Technology Partner in the Implementation of Biometric Solutions for NIISe

ImmVira announced to launch the construction of Global R&D and Commercialization Base

SHENZHEN, China, Oct. 18, 2022 /PRNewswire/ -- On October 18, 2022, ImmVira launched the construction of its Global R&D and Commercialization Base in Suzhou Wuzhong Biomedical Industrial Park (Lifebay),China. The day before, ImmVira's "Shanghai Business and Clinical Center" officially opened on t...

2022-10-18 16:22 993

ImmVira announced to launch the construction of Global R&D and Commercialization Base

EditForce Realizes RNA-editing Technology of "U-to-C"

FUKUOKA, Japan, Oct. 18, 2022 /PRNewswire/ -- EditForce, Inc. (hereinafter "EditForce"), headquartered inFukuoka, Japan, has realized the world's first RNA-editing technology that enables RNA-editing bases to be changed from "U" to "C," and demonstrated that this technology works even in human ce...

2022-10-18 14:00 1056

iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis

* The transposon technology development following the customized CRISPR/Cas system for bacteriophage * 2nd Generation technology of Robot Bacteriophage BOSTON and SEOUL, South Korea, Oct. 17, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com

2022-10-18 11:56 1301

GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies

SEOUL, South Korea, Oct. 18, 2022 /PRNewswire/ -- On the Oct 17, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and GeneCraft (Suk Chul Bae, CEO), a global research team led by Professor Suk Chul Bae of lung cancer mechanism research, announced that they had entered into a strat...

2022-10-18 08:00 1623

GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies

InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022

NANJING, China, Oct. 17, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology companydedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating t...

2022-10-18 08:00 986

TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM

* OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat disease. * PERTINENCE Early Phase I feasibility study of ...

2022-10-18 06:43 1339

GenScript ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) - the leading Thai-based Beauty & Health company, for the development and manufacturing of COVITRAP™ and future new products.

SINGAPORE, Oct. 17, 2022 /PRNewswire/ -- GenScript ProBio (a global one-stop CDMO from GenScript Group) today announced a strategic collaboration with Hibiocy Co. Ltd., a private corporation based inBangkok, Thailand, to accelerate a respiratory-care medical device, COVITRAP™ which contains human...

2022-10-17 23:56 4079

GenScript ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) - the leading Thai-based Beauty & Health company, for the development and manufacturing of COVITRAP™ and future new products.

Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia

Clinical trial assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicat...

2022-10-17 20:05 1044

PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022

DAEJEON, South Korea, Oct. 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company's first immuno-oncology dru...

2022-10-17 20:00 1014

Innovent Announces Phase Ib Results of Higher-dose Mazdutide (IBI362) in Chinese Participants with Overweight or Obesity Published in eClinicalMedicine

ROCKVILLE, Md. and SUZHOU, China, Oct. 17, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major d...

2022-10-17 08:00 3049

1 ... 106 107 108109110 111 112 ... 279